Chronic myeloid leukemia

Active Research Protocols

  1. 01-C-0125 – Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
  2. 01-H-0162 – Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using RFT5-SMPT-dgA, a Specific Anti-Interleukin-2 Receptor Immunotoxin: Reducing GVHD Risk Associated with HLA-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hemat
  3. 03-H-0192 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies √? Effect of Irradiated Donor Lymphocytes on Chimerism
  4. 04-C-0102 – Hematologic Malignancy Biology Study
  5. 04-H-0112 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Peritransplant Cyclosporine on Chimerism
  6. 06-C-0227 – Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Hematologic Malignancies
  7. 06-C-0233 – A Phase I/II Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias
  8. 06-H-0248 – Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back
  9. 07-C-0195 – Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
  10. 07-H-0136 – Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD after HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects with Hematologic Malignancies
  11. 07-H-0159 – Efficacy of WT1 and PRI Peptide Vaccination for Patients with Low Risk Myeloid Malignancies
  12. 08-C-0051 – A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
  13. 08-H-0186 – Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK√?TRAIL Cytotoxicity with Bortezomib
  14. 11-C-0125 – Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History
  15. 12-H-0028 – Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using Ex Vivo CD3, CD19 Depletion and CD34 Selection
  16. 97-H-0196 – A Phase II Study of HLA-Matched Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma as Adoptive Allogeneic Immunotherapy
  17. 97-H-0202 – Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults
  18. 99-H-0046 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine
  19. 99-H-0050 – Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014